Hayes, Inc. Advocates Evidence-Based Approaches to Diabetes Care

Share Article

Treatment approaches evolve, focus on better ways to improve patient outcomes

For the 24 million Americans living with diabetes and the 57 million more who are at risk of developing type 2 diabetes, treatment approaches continue to evolve as new research focuses on better ways to improve patient outcomes. During American Diabetes Month in November, Hayes, Inc. (http://www.hayesinc.com) urges clinicians and patients to learn as much as possible about new and emerging treatments for type 2 diabetes and to evaluate the evidence before making important medical decisions.

With the discovery of new medications, novel ways to deliver insulin, and weight-loss surgeries that may have the potential to eradicate type 2 diabetes in obese patients, it can be difficult for patients and their healthcare providers to determine which approach is best.

“With lifelong conditions such as diabetes, there’s an intense interest in new technologies such as new drugs and insulin-delivery systems,” says Jill Shuman, MS, RD, Senior Research Analyst at Hayes, Inc. and a Registered Dietitian. She cautions patients and providers to proceed with care. “Although anecdotal evidence may show that novel approaches result in good patient outcomes in the short term, it’s even more important to study the long-term evidence to see how new procedures and medications will affect patients after 5 or 10 years of follow-up.”

Risks and benefits often are not fully identified until thousands of people have been exposed to a particular treatment. This was the case with the antidiabetes medication troglitazone (Resulin®; Parke-Davis/Warner-Lambert, Morris Plains, NJ), which was removed from the U.S. market in 2000 after being linked to increased liver injury. More recently, the Food and Drug Administration (FDA) voted to make rosiglitazone (Avandia®; GlaxoSmithKline, Research Triangle Park, NC) available only under a restricted-access program after long-term study data suggested that it is associated with ischemic heart disease.

Comparative-effectiveness review (CER), which directly compares one intervention with another, is another tool available to patients, payers, and providers. “The direct comparison of treatments that is at the core of CER identifies which intervention offers the greatest benefits and which poses the greatest harms. This enables consumers and providers to make informed healthcare decisions,” says Shuman.

About Hayes, Inc.: Hayes, Inc. is an independent health technology research and consulting company dedicated to promoting better health outcomes through the use of evidence. Hayes performs unbiased, evidence-based health technology assessments of the safety and efficacy of new, emerging, and controversial health technologies and evaluates the impact of these technologies on healthcare quality, utilization, and cost. Hayes' worldwide clients include hospitals, healthcare systems, government agencies, employers, and managed care organizations. Hayes, Inc. monitors changing approaches to diabetes care through its News Service and reports breaking developments on its website.

For more information about Hayes, Inc. and its products and services, visit http://www.hayesinc.com. Or, contact Hayes, Inc. by mail at 157 S. Broad Street, Lansdale, PA 19446; by telephone at 215.855.0615; by e-mail at kmatthias(at)hayesinc(dot)com; or by fax at 215.855.5218.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website